PDF(Pubmed)
Abstract：
Differentiated high-grade thyroid carcinoma (DHGTC) is a new subset within the spectrum of thyroid malignancies. This review aims to provide a comprehensive overview of DHGTC, focusing on its historical perspective, diagnosis, clinical characteristics, molecular profiles, management, and prognosis. DHGTC demonstrates an intermediate prognosis that falls between well-differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Previously unenumerated, this entity is now recognized for its significant impact. Patients with DHGTC often present at an older age with advanced disease and exhibit aggressive clinical behavior. Molecularly, DHGTC shares similarities with other thyroid malignancies, harboring driver mutations such as BRAFV600E and RAS, along with additional late mutations. The unique behavior and histologic features of DHGTC underscore the necessity of precise classification for prognostication and treatment selection. This highlights the critical importance of accurate diagnosis and recognition by pathologists to enrich future research on this entity further.
摘要：
分化型高级别甲状腺癌（DHGTC）是甲状腺恶性肿瘤范围内的一个新子集。这篇综述旨在全面概述DHGTC，着眼于它的历史视角，诊断,临床特征,分子概况,管理,和预后。DHGTC显示介于高分化甲状腺癌和间变性甲状腺癌之间的中间预后。以前未列举的，这个实体现在因其重大影响而受到认可。DHGTC患者通常在患有晚期疾病的年龄较大时出现，并表现出侵袭性临床行为。分子上，DHGTC与其他甲状腺恶性肿瘤有相似之处，携带驱动突变，如BRAFV600E和RAS，以及额外的晚期突变。DHGTC的独特行为和组织学特征强调了对预后和治疗选择进行精确分类的必要性。这凸显了病理学家准确诊断和识别的至关重要性，以进一步丰富对该实体的未来研究。
